Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...
You must be a Standard 1 Year member to access this content.
Freshfields Bruckhaus Deringer is representing Johnson & Johnson in the transaction, and Fenwick & West is representing Shockwave Medical. Johnson & Johnson (NYSE: JNJ) and Shockwave Medical,...
You must be a Standard 1 Year member to access this content.
Fenwick & West and Goodwin Procter represented Gritstone bio, Inc. in the offering, and Cooley represented the underwriters. Gritstone bio, Inc. (Nasdaq: GRTS) announced the pricing of...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Coinbase Global, Inc. in the offering. Coinbase Global, Inc. (Nasdaq: COIN), a leading provider of end-to-end financial infrastructure and technology for the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised AppLovin Corporation on the deal, and Fenwick & West advised the underwriters. AppLovin Corporation (NASDAQ: APP) (“AppLovin” or the “Company”),...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Shockwave Medical, Inc. in the transaction. Shockwave Medical, Inc. (Nasdaq: SWAV) announced its $750 million offering of 1.00% convertible senior notes due 2028...
You must be a Standard 1 Year member to access this content.
Paul, Weiss, Rifkind, Wharton & Garrison LLP is advising MediPacific, Inc., while Fenwick & West LLP is advising Pardes Biosciences, Inc. in the transaction. MediPacific, Inc.,...
You must be a Standard 1 Year member to access this content.
Fenwick represented Coinbase Global, Inc. on the deal. Coinbase Global, Inc. (Nasdaq: COIN), a leading provider of end-to-end financial infrastructure and technology for the cryptoeconomy, announced...
You must be a Standard 1 Year member to access this content.
Fenwick represented Morphic Holding, Inc. on the deal. Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment...
You must be a Standard 1 Year member to access this content.
Fenwick advised Shockwave Medical, Inc. on the deal. Shockwave Medical, Inc. (NASDAQ: SWAV), a medical device company focused on the development of Intravascular Lithotripsy (IVL) to...
You must be a Standard 1 Year member to access this content.
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
You must be a Standard 1 Year member to access this content.
